Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RAawm-aFsVya5KjD3tqxJLybxpsX-434ijIcM-Nuhy85M#assertion>. }
Showing items 1 to 30 of
30
with 100 items per page.
- subject C0011777 "dexamethasone" assertion.
- object C1704419 "effective" assertion.
- object C1280519 "effective" assertion.
- object C5203670 "COVID-19" assertion.
- subject C0087111 "therapy" assertion.
- subject C0025815 "methylprednisolone" assertion.
- object C0030705 "patients" assertion.
- subject C3536709 "corticosteroid" assertion.
- subject C0001617 "corticosteroid" assertion.
- object C4552904 "risk" assertion.
- object C0035647 "risk" assertion.
- subject C1363945 "therapy" assertion.
- subject C3844638 "either" assertion.
- object C1155266 "inflammatory response" assertion.
- object C0424295 "hyper" assertion.
- subject C1947910 "pulse" assertion.
- subject C0444956 "high dose" assertion.
- subject C0391850 "pulse" assertion.
- subject C0232117 "pulse" assertion.
- subject C0034107 "pulse" assertion.
- predicate select?q=TRIPLE_UID:wm11rufi-TRIPLE-ABSTRACT-6 "be" assertion.
- object C1273869 "intervention" assertion.
- object C0886296 "intervention" assertion.
- object C0184661 "intervention" assertion.
- object C0038954 "survival rates" assertion.
- triple label "high dose corticosteroid pulse therapy ( HDCPT ) with either methylprednisolone or dexamethasone be an effective intervention to increase COVID-19 survival rates in patients at risk of developing a COVID-19 hyper - inflammatory response" assertion.
- sentence label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone can be an effective intervention to increase COVID-19 survival rates in patients at risk of developing a COVID-19 hyper-inflammatory response, laboratory marker tests can be used to stratify these patients." assertion.
- version value "1" assertion.
- assertion wasGeneratedBy "S&T TWOC project version 1" assertion.
- Triple-UID select?q=TRIPLE_UID:wm11rufi-TRIPLE-ABSTRACT-6 "wm11rufi-TRIPLE-ABSTRACT-6" assertion.